Solvias is a Switzerland-based manufacturing and pharmaceutical company, established in 1999. With the slogan "Solvias is a world leader in pharmaceutical CMC analysis (CRO)," the company offers CMC analytical solutions for innovative companies. Solvias boasts deep scientific expertise and a strong focus on customer success, providing comprehensive solutions for small molecules, biologics, and cell and gene therapies.
The company operates from five strategically located global facilities in biopharmaceutical hubs and is GMP, GLP, and ISO certified. They conduct over 100 successful customer audits annually, emphasizing their commitment to science and quality at every level.
Solvias' services span from raw materials to final release testing, as well as API development and manufacturing for small molecules, positioning them as a trusted analytical partner for the entire development journey. Their extensive expertise and capabilities enable them to solve even the most complex analytical challenges, supporting their customers in bringing better and safer products to market faster.
Currently, there is no publicly disclosed information about Solvias' latest investment and associated investors.
There is no investment information
No recent news or press coverage available for Solvias.